- Home
- CANF vs GNS Comparison
CANF vs GNS Comparison
Compare CANF & GNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- GNS
- Stock Information
- Founded
- CANF 1994
- GNS 2002
- Country
- CANF Israel
- GNS Singapore
- Employees
- CANF N/A
- GNS N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- GNS Other Consumer Services
- Sector
- CANF Health Care
- GNS Real Estate
- Exchange
- CANF Nasdaq
- GNS Nasdaq
- Market Cap
- CANF 14.4M
- GNS 15.9M
- IPO Year
- CANF N/A
- GNS 2022
- Fundamental
- Price
- CANF $2.01
- GNS $0.90
- Analyst Decision
- CANF Strong Buy
- GNS
- Analyst Count
- CANF 2
- GNS 0
- Target Price
- CANF $14.00
- GNS N/A
- AVG Volume (30 Days)
- CANF 63.2K
- GNS 11.6M
- Earning Date
- CANF 11-26-2024
- GNS 11-26-2024
- Dividend Yield
- CANF N/A
- GNS N/A
- EPS Growth
- CANF N/A
- GNS N/A
- EPS
- CANF N/A
- GNS N/A
- Revenue
- CANF $667,000.00
- GNS $23,062,754.00
- Revenue This Year
- CANF $409.56
- GNS $39.87
- Revenue Next Year
- CANF N/A
- GNS $32.96
- P/E Ratio
- CANF N/A
- GNS N/A
- Revenue Growth
- CANF N/A
- GNS 26.76
- 52 Week Low
- CANF $1.87
- GNS $0.51
- 52 Week High
- CANF $4.69
- GNS $9.49
- Technical
- Relative Strength Index (RSI)
- CANF 38.15
- GNS 57.05
- Support Level
- CANF $1.93
- GNS $0.79
- Resistance Level
- CANF $2.21
- GNS $1.14
- Average True Range (ATR)
- CANF 0.20
- GNS 0.20
- MACD
- CANF -0.02
- GNS 0.04
- Stochastic Oscillator
- CANF 15.52
- GNS 42.22
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About GNS Genius Group Limited
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. The company's business consists of two reportable business segments: Education - entrepreneur education, management consultancy, and business development tools; and Campus - resorts, retreats, and co-working cafes for entrepreneurs. It derives the majority of its revenue from the Education segment.